Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of mepolizumab for severe uncontrolled refractory asthma
2009-014415-12Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mepolizumab in asthma (4 arms), sponsored by GSK. Primary endpoint: Frequency of clinically significant asthma exacerbations. Started Sep 2009; status: completed.
02
Drugs
mepolizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2009-014415-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014415-12.